Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1653 in healthy adults
NCT03392389Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Dec 2017
- Primary completion
- Jul 2019
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human metapneumovirus infection (HMPV) and human parainfluenza virus type 3 infection (PIV3) comparing mRNA-1653 with Placebo (2 arms). Primary endpoints: Frequency of solicited local and systemic reactogenicity events, Frequency of unsolicited adverse events and 5 more. Started Dec 2017; status: completed.
02
Drugs
mRNA-1653
03
Conditions
human metapneumovirus infection (HMPV)human parainfluenza virus type 3 infection (PIV3)
Beyond the preview
Go deeper on NCT03392389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03392389.